Page 4 - Ghost Cytometry News Today : Breaking News, Live Updates & Top Stories | Vimarsana

ThinkCyte Secures $26 million in Series B Financing Funding will be used to advance the development of AI-based cell analysis and sorting platforms in cell therapy and diagnostics. News provided by Share this article Share this article TOKYO, May 19, 2021 /PRNewswire/ -- ThinkCyte, Inc., a company focusing on the development of novel cell therapy, drug discovery and diagnostic platforms, announced today the completion of a $26 million (JPY 2.85 billion) Series B financing, led by SPARX Group with participation from Sysmex Corporation and Sumitomo Mitsui Trust Investment as well as existing ...

Sysmex and ThinkCyte Agree on Joint Development and Capital Alliance - Commencing development of novel AI-based cell analyzers and testing techniques - News provided by Share this article Share this article TOKYO, May 12, 2021 /PRNewswire/ -- Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) and ThinkCyte, Inc. (HQ: Bunkyo-ku, Tokyo, Japan; CEO: Waichiro Katsuda) announced today the signing of joint development and investment agreements during May 2021 for the commercialization of an AI-based cell analysis technology. As healthcare becomes more precise and personalized a...